Lung cancer is one of the most frequently diagnosed cancers and is the leading cause of
cancer-related death worldwide. Non-small-cell lung cancer (NSCLC), a heterogeneous class …

Resistance to RAF- and MEK-targeted therapy is a major clinical challenge 1 , 2 , 3 , 4 . RAF
and MEK inhibitors are initially but only transiently effective in some but not all patients with …

Non-small-cell lung cancer is often diagnosed at the metastatic stage, with median survival
of just 1 year. The identification of driver mutations in the epidermal growth factor receptor (…

Purpose In addition to prospective trials for non–small-cell lung cancers (NSCLCs) that are
driven by less common genomic alterations, registries provide complementary information on …

One strategy for combating cancer-drug resistance is to deploy rational polytherapy up front
that suppresses the survival and emergence of resistant tumor cells. Here we demonstrate in …

Purpose: Concomitant genetic alterations could account for transient clinical responses to
tyrosine kinase inhibitors of the EGF receptor (EGFR) in patients harboring activating EGFR …

Importance The EURTAC trial demonstrated the greater efficacy of erlotinib compared with
chemotherapy for the first-line treatment of European patients with advanced non–small-cell …

Epidermal growth factor receptor (EGFR) gene mutations and increased EGFR copy numbers
have been associated with a favorable response to EGFR tyrosine kinase inhibitors (TKI) …

Background: Programmed death-ligand 1 (PD-L1) may be induced by oncogenic signals or
can be upregulated via interferon gamma (IFN-γ). We have explored whether the expression …

Neoantigens, which are expressed on tumor cells, are one of the main targets of an effective
antitumor T-cell response. Cancer immunotherapies to target neoantigens are of growing …